Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment

prnasiaJanuary 18, 2022

Tag: CStone , Sugemalimab , ESCC

PharmaSources Customer Service